



Atty. Dkt. No. 032931-0264

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Andrew D. MURDIN et al.

Title: CHLAMYDIA ANTIGENS AND CORRESPONDING
DNA FRAGMENTS AND USES THEREOF

Appl. No.: 10/608,559

Filing Date: 06/30/2003

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. or cited by or submitted to the U.S. PTO in parent application Serial No. 09/564,479, filed 05/03/2000. A copy of Document A1 is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98. As provided in 37 CFR §1.98(d), copies of the Documents A2 – A57 are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Jan 14, 2004

By Michele M. Simkin

FOLEY & LARDNER

Customer Number: 22428

Telephone: (202) 672-5538

Facsimile: (202) 672-5399

Michele M. Simkin

Attorney for Applicants

Registration No. 34,717

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 14, 2004

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	10/608,559
Filing Date	06/30/2003
First Named Inventor	Andrew D. Murdin
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	032931-0264

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	6,559,294	B1	GRIFFAIS ET AL.	05/06/2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A2	EP	0 784 059	A		07/16/1997		
	A3	WO	98/58953	A		12/30/1998		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A4	GRAYSTON et al., "Evidence That Chlamydia Pneumoniae Causes Pneumonia And Bronchitis", <i>The Journal of Infectious Diseases</i> , Vol. 168(5):1231-1491, (1993)	
	A5	CAMPOS et al., "a Chlamydial Major Outer Membrane Protein Extract As A Trachoma Vaccine Candidate", <i>Investigative Ophthalmology & Visual Science</i> , Vol. 36(8): (1995)	
	A6	GRAYSTON et al., "A New Respiratory Tract Pathogen: Chlamydia Pneumoniae Strain TWAR", <i>The Journal of Infectious Diseases</i> , Vol. 161, pp. 618-625, (1990)	
	A7	T. MARRIE, "State-of-the-Art Clinical Article", <i>Clinical Infectious Diseases</i> , Vol. 18, pp. 501-515, (1994)	
	A8	WANG et al., "Microimmunofluorescence Serological Studies With The Twar Organism", <i>Chlamydial Infections</i> , pp. 329-333, (1986)	
	A9	SAIKKU et al., "Serological Evidence Of An Association Of A Novel Chlamydia, Twar, With Chronic Coronary Heart Disease And Acute Myocardial Infarction", <i>The Lancet</i> , pp. 983-985, (1988)	
	A10	THOM et al., "Association of Prior Infection With Chlamydia Pneumoniae And Angiographically Demonstrated Coronary Artery Disease", <i>JAMA</i> , Vol. 268(1):68-72	
	A11	KUO et al., "Demonstration of Chlamydia Pneumoniae In Atherosclerotic Lesions Of Coronary Arteries", <i>The Journal of Infectious Diseases</i> , Vol. 167:841-849, (1993)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 14, 2004 (Use as many sheets as necessary)		Complete if Known	
Application Number		10/608,559	
Filing Date		06/30/2003	
First Named Inventor		Andrew D. Murdin	
Group Art Unit		1645	
Examiner Name		Unassigned	
Attorney Docket Number		032931-0264	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A12	KUO et al., "Detection of Chlamydia Pneumoniae In Aortic Lesions of Atherosclerosis By Immunocytochemical Stain", <i>Arteriosclerosis and Thrombosis</i> , Vol. 13(10):1501-1504, (1993)	
	A13	CAMPBELL et al., "Detection Of Chlamydia Pneumoniae TWAR In Human Coronay Atherectomy Tissues", <i>The Journal Of Infectious Diseases</i> , Vol. 172:585-588, (1995)	
	A14	CHIU et al., "Chlamydia Pneumoniae, Cytomegalovirus, And Herpes Simplex Virus In Atherosclerosis Of The Carotid Artery", <i>Circulation</i> , Vol. 96(7):2144-2148, (1997)	
	A15	RAMIREZ, "Isolation Of Chlamydia Pneumoniae From The Coronary Artery Of A Patient With Coronay Atherosclerosis", <i>Ann. Intern. Med.</i> , Vol. 125:979-982, (1996)	
	A16	JACKSON et al., Abst. K121, p. 272, 36 th ICAAC, 15-18 Sept. 1996, New Orleans	
	A17	FONG et al., "Rabbit Model For Chlamydia Pneumoniae Infection", <i>Journal Of Clinical Microbiology</i> , Vol. 35(1):48-52, (1997)	
	A18	HAHN et al., "Evidence For Chlamydia Pneumoniae Infection In Steroid-Dependent Asthma", <i>Ann. Allergy Asthma Immunol.</i> , Vol. 80(1):45-49, (1998)	
	A19	HAHN et al., "Association Of Chlamydia Pneumoniae IgA Antibodies With Recently Symptomatic Asthma", <i>Epidemiol. Infect.</i> , Vol. 117:513-517, (1996)	
	A20	BJOERNSSON et al., "Serology Of Chlamydia In Relation To Asthma And Bronchial Hyperresponsiveness", <i>Scand. J. Infect. Dis.</i> , Vol. 28:63-69, (1996)	
	A21	HAHN, "Treatment Of Chlamydia Pneumoniae Infection In Adult Asthma: A Before-After Trail", <i>J. Fam. Pract.</i> , Vol. 41(4):345-351, (1995)	
	A22	LINNANMAEKI et al., "Chlamydia Pneumoniae-Specific Circulating Immune Complexes In Patients With Chronic Coronary Heart Disease", <i>Circulation</i> , Vol. 87(4):1130-1134, (1993)	
	A23	SAIKKU et al., "Annals Of Internal Medicine", <i>American College of Physicians</i> , Vol. 116(4):273-278, (1992)	
	A24	MELNICK et al., "Past Infection by Chlamydia Pneumoniae Strain TWAR and Asymptomatic Carotid Atherosclerosis", <i>The American Journal of Medicine</i> , Vol. 95:499-504, (1993)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 14, 2004

Use as many sheets as necessary)

3 of 5

Complete if Known

Application Number	10/608,559
Filing Date	06/30/2003
First Named Inventor	Andrew D. Murdin
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	032931-0264

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A25	SHOR et al., "Detection of Chlamydia Pneumoniae In Coronary Arterial Fatty Streaks And Atheromatous Plaques", <i>South African Medical Journal</i> , Vol. 82:158-161, (1992)	
	A26	ALLEGRA et al., "Acute Exacerbations Of Asthma In Adults: Role Of Chlamydia Pneumoniae Infection", <i>Eur.Respir. J.</i> , Vol. 7(12): 2165-2168, (1994)	
	A27	HAHN et al., "Association of Chlamydia Pneumoniae (Strain TWAR) Infection With Wheezing, Asthmatic Bronchitis, and Adult-Onset Asthma", <i>JAMA</i> , Vol. 266(2):225-230, (1991)	
	A28	PAL et al., "Intranasal Immunization Induces Long-Term Protection In Mice Against A Chlamydia Trachomatis Genital Challenge", <i>Infection And Immunity</i> , Vol. 64(12):5341-5348, (1996)	
	A29	JONES et al., "Efficacy Trials With Tissue-Culture Grown, Inactivated Vaccines Against Chlamydial Abortion In Sheep", <i>Vaccine</i> , Vol. 13(8):715-723, (1995)	
	A30	IGIETSEME et al., "Resolution Of Murine Chlamydial Genital Infection By The Adoptive Transfer Of A Biovar-Specific, TH1 Lymphocyte Clone", <i>Regional Immunology</i> , Vol. 5:317-324, (1993)	
	A31	MAGEE et al., "Chlamydia Trachomatis Pneumonia In The Severe Combined Immunodeficiency (SCID) Mouse", <i>Reg. Immunol.</i> , Vol. 5:305-311, (1993)	
	A32	GAYDOS et al., "Similarity of Chlamydia Pneumoniae Strains In The Variable Domain IV Region Of The Major Outer Membrane Protein Gene", <i>Infection And Immunity</i> , Vol. 60(12):5319-5323, (1992)	
	A33	Database Trembl 'Online!' EBI, Hinxton, U.K.; 1 May 1999; XP002150537; CHLPN 76 KDA HOMOLOG_1 (CT622).	
	A34	PEREZ, Melgoza M. et al., "Isolation and Characterization of a Gene Encoding a Chlamydia pneumoniae 76-Kilodalton Protein Containing a Species-Specific Epitope", <i>Infection and Immunity</i> , 1 March 1994, US, American Society for Microbiology, Washington, vol. 62, no. 3, pp. 880-886.	
	A35	KALMAN ET AL., <i>Nature Genetics</i> . April 1999, 21:385-389.	

**Examiner
Signature**
**Date
Considered**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 14, 2004

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	10/608,559
Filing Date	06/30/2003
First Named Inventor	Andrew D. Murdin
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	032931-0264

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A36	CASEY et al., "Rates Of Formation And Thermal Stabilities Of RNA:DNA and DNA:DNA Duplexes At High Concentrations of Formamide", <i>Nucleic Acids Research</i> , Vol. 4(5):1539-1553, (1977)	
	A37	CAGNON et al., "A New Family Of Sugar-Inducible Expression Vectors For Escherichia Coli", <i>Protein Engineering</i> , Vol. 4(7):843-847, (1991)	
	A38	WIEDMANN-AL-AHMAD et al., "Reactions of Polyclonal And Neutralizing Anti-p54 Monoclonal Antibodies With An Isolated, Species-Specific 54-Kilodalton Protein Of Chlamydia Pneumoniae", <i>Clinical And Diagnostic Laboratory Immunology</i> , Vol. 4(6):700-704, (1997)	
	A39	HUGHES et al., "Synthetic Peptides Representing Epitopes Of Outer Membrane Protein F Of Pseudomonas Aeruginosa That Elicit Antibodies Reactive With Whole Cells Of Heterologous Immunity Strains of P.Aeruginosa", Vol. 60(9):3497-3503, (1992)	
	A40	DION et al., "Virus Envelope-Based Peptide Vaccine Against Virus-Induced Mammary Tumors", <i>Virology</i> , Vol. 179:474-477, (1990)	
	A41	SNIJDERS et al., "Identification Of Linear Epitopes On Semliki Forest Virus E2 Membrane Protein And Their Effectiveness As A Synthetic Peptide Vaccine", <i>Journal of General Virology</i> , Vol. 72:557-565, (1991)	
	A42	LANGEVELD et al., "Effective Induction of Neutralizing Antibodies With The Amino Terminus Of VP2 Of Canine Parvovirus As A Synthetic Peptide", <i>Vaccine</i> , Vol. 12(15):1473-1480, (1994)	
	A43	AUSUBEL et al., "Analysis Of DNA Sequences By Blotting And Hybridization", <i>Current Protocols In Molecular Biology</i> , pp. 2.9.1-2.9.15, (1994)	
	A44	KLUNKEL, "Rapid And Efficient Site-Specific Mutagenesis Without Phenotypic Selection", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82:488-492, (1985)	
	A45	SILHAVY et al., "Experiments With Gene Fusions", <i>Cold Spring Harbor Laboratory</i> , pp. 191-195, (1984)	
	A46	LANDERS et al., "Role of L3T4-Bearing T-Cell Populations In Experimental Murine Chlamydial Salpingitis", <i>Infection and Immunity</i> , Vol. 59(10):3774-3777, (1991)	

 Examiner
Signature

 Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 14, 2004

(Use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	10/608,559
Filing Date	06/30/2003
First Named Inventor	Andrew D. Murdin
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	032931-0264

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A47	MAGEE et al., "Role Of CD8 T Cells In Primary Chlamydia Infection", <i>Infection and Immunity</i> , Vol. 63(2):516-521, (1995)	
	A48	COTTER et al., "Protective Efficacy of Major Outer Membrane Protein-Specific Immunoglobulin A (IgG Monoclonal Antibodies In A Murine Model Of Chlamydia Trachomatis Genital Tract Infection", <i>Infection And Immunity</i> , Vol. 63(12):4704—4714, (1995)	
	A49	CAMPBELL et al., "Structural And Antigenic Analysis Of Chlamydia Pneumoniae", <i>Infection and Immunity</i> , Vol. 58(1):93-97, (1990)	
	A50	MCCAFFERTY et al., "Electrophoretic Analysis Of The Major Outer Membrane Protein Of Chlamydia Psitaci Reveals Multimers Which Are Recognized By Protective Monoclonal Antibodies", <i>Infection And Immunity</i> , Vol. 63(6):2387-2389, (1995)	
	A51	TAKASE ET AL., "Genes Encoding Two Lipoproteins In the leuS0dacA Region of the Escherichia Coli Chromosome," <i>Journal of Bacteriology</i> , Vol. 169: 5692-5699, (1987).	
	A52	MELGOSA et al., "Isolation and Characterization of a Gene Encoding A Chlamydia Pneumoniae 76-Kilodalton Protein containing A Species-Specific Epitope," <i>Infection and Immunity</i> , Vol. 62(3):880-886, (1994).	
	A53	CAMPBELL ET AL., "Serological Response to Chlamydia Pneumoniae Infection," <i>FEMS Microbiology Letters</i> , Vol. 112: 199-204, (1993).	
	A54	IJIMA ET AL., "Characterization of Chlamydia Pneumoniae Species-Specific Proteins Immunodominant In Humans," <i>Journal of Clinical Microbiology</i> , Vol. 32(3): 583-588, (1994).	
	A55	http://chlamydia-www.berkeley.edu:4231/	
	A56	BACHMAIER ET AL., "Chlamydia Infections and Heart Disease Linked Through Antigenic Mimicry," <i>Science</i> , Vol. 283:1335-1339, (1999).	
	A57	DAVIS et al., "A Manual For Genetic Engineering Advanced Bacterial Genetics", <i>Cold Spring Harbor Laboratory</i> , pp. 174-176, (1980)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.